External Publication
Visit Post

Johnson & Johnson (JNJ) Q4 2025 Earnings — Core Brief Edition

Core-Brief February 8, 2026
Source

Headline: J&J exited 2025 with broad-based momentum (despite a large Stelara headwind), guided to ~$100B+ 2026 revenue, and reiterated line-of-sight to double-digit growth by the back half of the decade—supported by oncology/immunology launches, MedTech acceleration, and continued portfolio reshaping (Ortho separation).

Key Metrics

  • Q4 worldwide sales: $24.6B (+7.1% operational).
  • FY2025 worldwide sales: $94.2B (+5.3% operational).
  • Q4 GAAP net earnings / EPS: $5.1B ; $2.10 (vs $1.41 prior year).
  • Q4 adj. net earnings / adj. EPS: $6.0B ; $2.46 (+21.5% / +20.6% YoY).
  • FY2025 GAAP EPS: $13.00 (included $7.0B talc reserve reversal in Q1).
  • FY2025 adj. net earnings / adj. EPS: $26.2B ; $10.79 (+8.1% YoY).
  • FY2025 free cash flow: $19.7B ; FY2026 FCF outlook: ~$21B.
  • Cash / debt (end-2025): ~$20B cash & marketable securities; $48B debt; ~$28B net debt.
  • Q4 segment sales: Innovative Medicine $15.8B (+7.9% op); MedTech $8.8B (+5.8% op).
  • Adjusted income before tax margin (enterprise, Q4): 28.7% (vs 24.1% prior year).

Segment & Strategy Highlights

Innovative Medicine (Q4 sales: $15.8B, +7.9% op)

  • Oncology : Strong multiple myeloma franchise.
    • Darzalex: +24.1% (share gains + market growth).
    • Carvykti: $555M , +63.2% (share gains + expansion); > 10,000 patients treated across 14 markets (management cited).
    • Rybrevant + Lazcluze: $216M , +76.5% (launch uptake; share gains in 1L/2L).
  • Immunology :
    • Tremfya: +65.4% ; management: > $5B FY sales for first time and targets > $10B peak.
    • Stelara: -48.6% (biosimilar competition + Part D redesign).
    • Upcoming: icotrokinra / “icotide” (oral IL-23) anticipated US approval/launch in 2026 (psoriasis first; IBD later).
  • Neuroscience :
    • Spravato: +67.8% (strong demand).
    • Caplyta: $249M in Q4 (acquired via Intracellular); cited highest-ever new patient starts post-MDD approval.

MedTech (Q4 sales: $8.8B, +5.8% op)

  • Cardiovascular :
    • Abiomed: +18.3% (Impella adoption).
    • Shockwave: +22.9% (coronary + peripheral adoption); became 13th billion-dollar MedTech platform.
    • EP/PFA: Q4 EP growth cited at +6.5% overall; leadership push with Varipulse and pipeline cadence (new catheter “every year” through decade end; ~40,000 AF patients treated with Varipulse cited).
  • Surgery: +3.7% (headwinds: competition; China VBP; portfolio actions). Highlighted Ethicon 4000 stapler launch; Ottava de novo FDA submission.
  • Vision: Contact lenses & surgical vision solid.
    • Contact lens/other products: +5.3% (category growth + price actions).
    • Surgical vision: +10.8% (premium IOL demand; Technis Odyssey momentum; planned US launch of Technis PureSee in 2026).

Portfolio / Capital deployment

  • Continued transformation toward “higher-growth, higher-margin” markets; Ortho separation targeted mid-2027.
  • 2025 investment cited as “over” a large amount (exact figure not clearly stated) including acquisitions (Intracellular, Haldor Therapeutics) + US manufacturing buildout.

Product, Tech, AI / Devices (if discussed)

  • Anexo (bladder cancer drug-device system): initial FDA approval (Sept); positive early launch commentary; permanent J-code expected early Q2 (April).
  • Platform expansion: TAR-210 (erlotinib payload device) targeting intermediate-risk; management cited > 90% CR rates (as discussed on the call).
  • Robotics : Monarch urology robotics; Ottava robot via de novo pathway (no predicate device claimed).

Credit & Risk (only if applicable)

  • Talc litigation: Management addressed Daubert/Special Master report; plans to appeal portions; reiterated intent to litigate aggressively and said it doesn’t change strategy (no reserve change guidance provided).

Balance Sheet & Capital

  • End-2025: ~$20B cash & marketable securities; $48B debt; ~$28B net debt.
  • FY2025 FCF: $19.7B ; FY2026 FCF outlook: ~$21B.
  • Share count: diluted share count expected ~2.44B in 2026; ~$0.05 EPS headwind vs 2025 due to dilution mechanics (as described).

Guidance / Outlook

  • FY2026 operational sales growth: 5.7%–6.7% (midpoint ~$100B , +6.2%).
    • Acquisitions: ~+30 bps tailwind to operational growth (midpoint adjusted operational growth ~5.9%).
    • 53rd week : adds ~100 bps benefit.
  • FY2026 reported sales growth: 6.2%–7.2% (midpoint $100.5B , +6.7%) based on stated FX methodology.
  • FY2026 adj. pre-tax operating margin: improvement of ≥50 bps (includes ~$500M MedTech tariffs; includes impact of voluntary US government agreement to improve access/lower costs).
  • Net interest expense: $300M–$400M.
  • Net other income: $1.0B–$1.2B.
  • Effective tax rate: 17.5%–18.5%.
  • FY2026 adj. EPS: $11.28–$11.48 (midpoint growth ~+5.5%).
    • Reported adj. EPS midpoint: $11.53 (includes +$0.15 FX benefit per management).

Bottom Line

J&J is framing 2025 as the “catapult” year: core Innovative Medicine brands (notably oncology and Tremfya) are scaling fast enough to offset Stelara erosion, while MedTech is leaning into CV/EP momentum, surgical robotics (Ottava), and premium vision. Guidance implies another solid year with ≥50 bps margin expansion despite ~$500M MedTech tariff headwinds, and management is leaning hard on a pipeline/launch cadence that supports double-digit growth aspirations later in the decade.

Discussion in the ATmosphere

Loading comments...